Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 2/20 | 0.48 |
| ▸ | MC5R | P33032 | 2/20 | 0.48 |
| ▸ | MC3R | P41968 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7857952 | 0.92 | HDAC8 (0.57) | NLNHDAC8DPP4OPRD1 | |
| SCHEMBL7857956 | 0.92 | HDAC8 (0.57) | NLNHDAC8DPP4OPRD1 | |
| SCHEMBL5556817 | 0.86 | NLN (0.62) | NLNDPP4MC4RMC5RMC3R | |
| SCHEMBL14861105 | 0.86 | CA12 (0.61) | CA12CA1CA2HDAC8 | |
| SCHEMBL6961215 | 0.86 | CA12 (0.61) | CA12CA1CA2HDAC8 | |
| SCHEMBL13073331 | 0.86 | CA12 (0.61) | CA12CA1CA2HDAC8 | |
| SCHEMBL1769595 | 0.86 | NLN (0.50) | NLNDPP4OPRD1 | |
| SCHEMBL1769590 | 0.86 | NLN (0.50) | NLNDPP4OPRD1 | |
| SCHEMBL5125551 | 0.86 | NLN (0.50) | NLNDPP4MC4RMC5RMC3R | |
| SCHEMBL12520303 | 0.86 | NLN (0.50) | NLNDPP4OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | CA12 2461/4885CA1 1823/4885CA2 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.